News und Analysen
Better Buy: Novavax, Inc. vs. Pfizer Inc.
Pfizer (NYSE: PFE) ranks as one of the giants of the pharmaceutical market, with a blockbuster vaccine franchise. Novavax (NASDAQ: NVAX) is only a fraction of Pfizer's size and is still at least a....
Better Buy: Novavax, Inc. vs. Pfizer Inc.
Pfizer (NYSE: PFE) ranks as one of the giants of the pharmaceutical market, with a blockbuster vaccine franchise. Novavax (NASDAQ: NVAX) is only a fraction of Pfizer's size and is still at least a....
Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October
Shares of AVEO Pharmaceuticals (NASDAQ: AVEO), a small-cap biopharma focused on cancer, fell 18.6% in October, according to data from S&P Global Market Intelligence. There doesn't appear to be....
The Only 3 Big Pharma Companies Growing Market Share
With worldwide spending on prescription drugs increasing from an estimated $774 billion in 2017 to over $1 trillion in 2022, a rising tide of pharmaceutical sales is lifting a lot of drug company....
Why Henry Schein, Inc. Is Falling
In response to the company's third-quarter earnings, shares of Henry Schein (NASDAQ: HSIC), a maker of medical products that are primarily used by dentists and veterinarians, fell as much as 10%....
Why Henry Schein, Inc. Is Falling
In response to the company's third-quarter earnings, shares of Henry Schein (NASDAQ: HSIC), a maker of medical products that are primarily used by dentists and veterinarians, fell as much as 10%....
Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby
Exelixis (NASDAQ: EXEL), the biotech once left for dead by quite a few investors, continues its resurgence with another solid quarter of sales of its kidney cancer drug Cabometyx. Of course, the....
Keryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't Matter
Shares of Keryx Biopharmaceuticals (NASDAQ: KERX), a commercial-stage biopharma focused on kidney disease, fell 8.6% in October according to data from S&P Global Market Intelligence. However,....
Here's Why Stemline Therapeutics Inc. Jumped 23% Higher in October
Shares of Stemline Therapeutics Inc. (NASDAQ: STML), a clinical-stage biotech developing therapies that target cancer stem cells, shot up 23% in October according to data from S&P Global....
BASTIDE : Déclaration du nombre d'actions et de droits de vote (31.10.2017)
BASTIDE LE CONFORT MEDICAL
Société Anonyme au capital de 3.303.261 euros
Siège social : 12 avenue de la Dame, Zone Euro 2000
30132 Caissargues
RCS de NIMES N° B 305 635 039
DROITS DE....
What's Behind GW Pharmaceuticals' 6.4% Gain in October?
Shares of GW Pharmaceuticals plc (NASDAQ: GWPH), a company developing an epilepsy drug derived from its cannabinoid product platform, tacked on another 6.4% in October according to data from....
GW Pharmaceuticals Just Delivered Some Good News About Its Marijuana-Based Drug
This year has been a real seesaw for shareholders of GW Pharmaceuticals (NASDAQ: GWPH). Lately, that seesaw is tipping up slightly, following news that a cannabidiol-based drug candidate the....
3 Stocks Changing the Future of Healthcare
The healthcare sector is in the midst of an unprecedented technological boom at the moment. Despite major advancements across several medical fields, though, this innovation bonanza is, quite....
3 Stocks to Buy for a Better Tomorrow
Buy low, and sell high. In investing, as in life, we all hope for "a better tomorrow," and one in which the decisions we make today ultimately pay off -- figuratively, and, in the case of stocks,....
5 Dividend Aristocrats With the Fastest-Growing Dividends
Many investors like to buy stocks that are known as Dividend Aristocrats. To join this elite group, an S&P 500 company must increase its dividend for at least 25 consecutive years. But just....
This Growing Robotics Company Is a Hit With Surgeons (Hint: It's not Intuitive Surgical)
Mazor Robotics Ltd.'s (NASDAQ: MZOR) surgical-assist robots are revolutionizing how surgeons perform spine surgery and demand for these systems could accelerate following study results showing....
True or False: Republicans Support Legalizing Marijuana?
Chances are that you'd struggle to find an industry within the U.S. that's growing at a faster and more consistent pace than legal marijuana.Colorado, one of the eight states that's legalized....
Affordable Care Act Enrollment: 5 Money-Saving Tips for 2018
It's that time of the year again: Open enrollment for the Affordable Care Act (ACA), which you probably know better as Obamacare, is in full swing. Enrollment began on Nov. 1, as it has in recent....
Affordable Care Act Enrollment: 5 Money-Saving Tips for 2018
It's that time of the year again: Open enrollment for the Affordable Care Act (ACA), which you probably know better as Obamacare, is in full swing. Enrollment began on Nov. 1, as it has in recent....
These 3 Stocks Just Raised Their Dividends
Thanksgiving came early to the stock exchange last week, with a score of companies declaring increases in their dividends. To some degree that's expected, given that we're in the swing of the fall....
Why This Marijuana Stock Imploded 42% in October
Medical marijuana upstart Insys Therapeutics (NASDAQ: INSY) had a ferociously frightening month, highlighted by the arrest of its founder, the setting aside of $150 million for lawsuits, and....
Why Celgene Crashed 30% in October -- and What Now?
Few industry watchers expected much out of GED-0301, yet its failure in a phase 3 study, plus anemic sales growth for one of its most important drugs, caused Celgene Corp. (NASDAQ: CELG) shares to....
Why Stamps.com, Pacific Biosciences of California, and Frontier Communications Slumped Today
Friday was another solid day for the stock market, and the Nasdaq Composite led most major benchmark indexes higher. Strong performance by the technology sector was a key driving force behind the....
Why Exact Sciences Shares Rallied 16.7% in October
After reporting third-quarter financial results that were better than expected, Exact Sciences (NASDAQ: EXAS) shares gained 16.7% in October, according to S&P Global Market Intelligence.Exact....
Why Investors Should Be Excited About Corcept Therapeutics Plunging as Much as 18%
Shares of Corcept Therapeutics (NASDAQ: CORT), a California-based drug developer that focuses on treating severe metabolic, oncologic, and psychiatric diseases, tumbled as much as 18% during....